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Tamoxifen is a ﬁrst-line endocrine agent in the mechanism-based treatment of estro-
gen receptor positive (ER+) mammary carcinoma and applied to breast cancer patients
all over the world. Endoxifen is a secondary and highly active metabolite of tamoxifen
that is formed among others by the polymorphic cytochrome P450 2D6 (CYP2D6). It is
widely accepted that CYP2D6 poor metabolizers exert a pronounced decrease in endoxifen
steady-state plasma concentrations compared to CYP2D6 extensive metabolizers. Never-
theless, an in-depth understanding of the chain of cause and effect between CYP2D6
genotype, endoxifen steady-state plasma concentration, and subsequent tamoxifen treat-
ment beneﬁt still remains to be evolved. In this study, physiologically based pharmacoki-
netic (PBPK)-modeling was applied to mechanistically investigate the impact of CYP2D6
phenotype on endoxifen formation in female breast cancer patients undergoing tamox-
ifen therapy. A PBPK-model of tamoxifen and its pharmacologically important metabolites
N -desmethyltamoxifen (NDM-TAM), 4-hydroxytamoxifen (4-OH-TAM), and endoxifen was
developed and validated. This model is able to simulate the pharmacokinetics (PK) after
single and repeated oral tamoxifen doses in female breast cancer patients in dependence
of the CYP2D6 phenotype. A detailed model-based analysis of the mass balance offered
support for a recent hypothesis stating a more prominent role for endoxifen formation
from 4-OH-TAM. In the future this model provides a good basis to further investigate the
linkage of PK, mode of action, and treatment outcome in dependence of factors such as
phenotype, ethnicity, or co-treatment with CYP2D6 inhibitors.
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INTRODUCTION
Tamoxifen is a ﬁrst-line endocrine agent in the adjuvant treat-
ment of estrogen receptor positive (ER+)-mammary carcinoma
and applied within a regular 5 year therapy regimen to patients all
over the world (Fisher et al., 2001; Goetz et al., 2008). Although
it represents a milestone in the mechanism-based treatment of
ER+-breast cancer, there is evidence that not all patients beneﬁt
from therapy (Jordan, 2006, 2007). In this context, the question of
whether or not cytochrome P450 2D6 (CYP2D6) polymorphisms
signiﬁcantly affect treatment outcome still remains controversially
discussed (Hoskins et al., 2009; Seruga and Amir, 2010; Brauch
et al., 2011; Rae, 2011).
An extensive hepatic metabolism of tamoxifen via CYP-
catalyzed phase I reactions leads to the formation of primary and
secondarymetabolites (Coller et al., 2002;Desta et al., 2004). These
are further glucuronidated or sulfated in phase II reactions cat-
alyzed by uridine-5′-diphospho-glucuronosyltransferases (UGT)
and sulfonyl-transferases (SULT; Nishiyama et al., 2002; Kaku
et al., 2004; Sun et al., 2007; Figure 1). The involvement of the
polymorphic CYP2D6 in the formation of the active secondary
metabolite endoxifen leads to inter-individual variability in its
plasma concentration due to for example single nucleotide poly-
morphisms affectingCYP2D6 enzyme activity (Zanger et al., 2001;
Coller et al., 2002; Stearns et al., 2003; Johnson et al., 2004; Lim
et al., 2006). It has been reported in the literature that CYP2D6
poor metabolizers (PM) show a pronounced decrease in endox-
ifen steady-state plasma concentrations in comparison to CYP2D6
extensive metabolizers (EM; Stearns et al., 2003; Jin et al., 2005;
Gjerde et al., 2008; Irvin et al., 2011; Madlensky et al., 2011;
Murdter et al., 2011). Most clinical trials reported up to now,
either assessed the correlation between CYP2D6 genotype and
endoxifen steady-state plasma concentration, or between CYP2D6
genotype and therapy outcome (Goetz et al., 2005, 2007; Borges
et al., 2006; Bijl et al., 2009; Lammers et al., 2010). However, the
linkage betweenCYP2D6 genotype, endoxifen steady-state plasma
concentration, and subsequent treatment beneﬁt needs further
investigation to achieve an in-depth understanding of the chain of
cause and effect (Lash et al., 2009; Fleeman et al., 2011).
To better understand the mass balance of tamoxifen and
the rate and extent of formation of its active metabolites, a
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FIGURE 1 | Main human biotransformation routes of tamoxifen.
Tamoxifen is mainly metabolized via the cytochrome P450 isoenzyme (CYP)
3A4/5 (CYP3A4/5) – catalyzed N -demethylation to N -desmethyltamoxifen
(NDM-tamoxifen) and subsequently 4-hydroxylated by the polymorphic
CYP2D6 to endoxifen. In a minor route, tamoxifen is 4-hydroxylated by
CYP2D6 and other CYP iso-forms to 4-hydroxytamoxifen (4-OH-tamoxifen) and
consequently N -demethylated to endoxifen. Sequential phase I or II reactions
of tamoxifen and metabolites occur via ﬂavin-containing monooxygenases
(FMO), CYPs, uridine-5′-diphospho-glucuronosyltransferases (UGT), or
sulfonyl-transferases (SULT).
physiologically based pharmacokinetic (PBPK)-model is desir-
able. PBPK-modeling comprises substance-speciﬁc as well as
anatomical and physiological species-speciﬁc parameters within
the mechanistic framework of a generic model structure (Will-
mann et al., 2003a). In short, every compartment represents a
single organ which is deﬁned by its physiological volume and is
further divided into sub-compartments representing the intracel-
lular, vascular (plasma and red blood cells), and interstitial space
(Figure 2; sub-compartments not shown). In the context of such a
PBPK-model, the inﬂuence of CYP2D6 enzyme activity on endox-
ifen pharmacokinetics (PK) can be studied (Zanger et al., 2001;
Coller et al., 2002). The PBPK-model described in this study will
further provide a starting point to investigate the pharmacoge-
nomics of tamoxifen treatment response after integration of a
mechanistic description of the mode of action of tamoxifen and
its active metabolites.
MATERIALS AND METHODS
PBPK-MODEL DEVELOPMENT WORKFLOW
To establish a PBPK-model for tamoxifen, plasma concentration–
time data after intravenous (i.v.) administration of tamoxifen
was highly desirable. Because – to the best of our knowledge –
no human data following i.v. dosing of tamoxifen is publically
available, a PBPK-model for the rat, for which i.v. data is avail-
able, was ﬁrst developed in order to describe the disposition
kinetics of tamoxifen. The rat PBPK-model was subsequently
scaled to an average European female individual of CYP2D6 EM
phenotype receiving oral tamoxifen. This female subject PBPK-
model was in the next step extended by PBPK-models for N -
desmethyltamoxifen (NDM-TAM), 4-hydroxytamoxifen (4-OH-
TAM), and endoxifen. Finally, the CYP2D6 EM-speciﬁc PBPK-
model was scaled to CYP2D6 PM using prior knowledge about
phenotype-speciﬁc CYP2D6 enzyme activity.
The modus operandi during each PBPK-model development
step was kept consistent and constant. A PBPK-model was built
with reference data in terms of species- and substance-speciﬁc
parameters (i.e., other generic parameters were kept on default
values) and model predictions were compared to corresponding
experimental data taken from the literature. If necessary, ﬁne-
tuning of parameters in a reasonable order of magnitude was
performed to improve model adequacy as detailed in the results.
SOFTWARE
Physiologically based pharmacokinetic-models were developed
and coupled by means of the computational systems biology soft-
ware platform including PK-Sim® 4.2.4 and MoBi® 2.3.5 (Bayer
Technology Services GmbH, Leverkusen, Germany)1. Subsequent
population simulations were conducted using the MoBi® Tool-
box for MATLAB® 2.2 (Bayer Technology Services GmbH, Lev-
erkusen, Germany; see text footnote 1 with MATLAB® from The
MathWorks, Inc., Natick, USA)2.
1www.systems-biology.com/products
2www.mathworks.com/products/matlab
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FIGURE 2 | Generic structure of the whole-body PBPK-model.The model
organism is built by compartments, each typically representing a single organ
deﬁned by its physiological volume. Organs are interconnected via respective
blood ﬂows which occur, except for pulmonary circulation, from the arterial
blood pool to the venous blood pool thus accounting for inter-compartmental
mass-transfer. Application of substances can be deﬁned as intravenous (i.v.),
per oral (p.o.), or into any desired compartment. In addition to clearance
events in intestinal wall, liver, and kidney, metabolism processes can be
implemented into any compartment. Transport processes that signiﬁcantly
inﬂuence a compound’s PK may be inserted between compartments.
A detailed description of the development of a coupled parent-
metabolite PBPK-model and population simulations comprising
explicitly modeled metabolites formed via polymorphic enzymes
was recently published (Eissing et al., 2011).
RESULTS
PBPK-MODEL DEVELOPMENT AND RESULTS
PBPK-model in rat
The physico-chemical parameters of tamoxifen that served as
input parameters for PK-Sim® are summarized in Table 1. As
can be seen in Figure 3, however, the volume of distribution
of tamoxifen in rats was not adequately described by the
set of physico-chemical parameters. After re-adjustment of the
lipophilicity input parameter in PK-Sim® (clog MA= 4.23 instead
of 3.43; Table 1), the plasma kinetics of tamoxifen in rat could
be very well described. The available experimental data demon-
strated an inﬂuence of gender on tamoxifen PK that could solely
be attributed to a gender-speciﬁc clearance in the model (Figure 3;
Table 4).
In summary, the established PBPK-model is able to correctly
describe tamoxifen disposition kinetics in rats on the basis of the
adjusted lipophilicity parameter.
www.frontiersin.org May 2012 | Volume 3 | Article 92 | 3
Dickschen et al. CYP2D6 phenotype-speciﬁc tamoxifen metabolites PBPK-model
Table 1 | Substance-specific physico-chemical parameters of tamoxifen used in the PBPK-model development.
Parameter Unit Reference value Used in simulation Reference
SUBSTANCE-SPECIFIC PARAMETERS USED INTHE RAT PBPK-MODEL OFTAMOXIFEN
Molecular weight g/Mol 371.52 371.52 PubChem
Clog MA*1 log unit 3.43 4.23 In-house method*2
Log D 37˚C*3 log unit 3.48 Custódio et al. (1991)
pK a log unit 8.36 8.36 Fagerberg et al. (2010)
f u (rat)*4 – 0.011 0.011 Yang et al. (2010)
SUBSTANCE-SPECIFIC PARAMETERSADDITIONALLY USED INTHE PBPK-MODEL OFTAMOXIFEN IN FEMALE INDIVIDUALS
In vitro intestinal permeability cm/s 2.067−5 2.067−5 Willmann et al. (2004)
Solubility (tamoxifen citrate) mg/L 329 329 Buchanan et al. (2007)
Clog K d HSA*5 M −4.52 In-house method
K a HSA*6 M−1 1.8*104 Bourassa et al. (2011)
K d HSA M 5.56*10−5 Bourassa et al. (2011)
Log K d HSA M −4.26 −4.26 Bourassa et al. (2011)
f u (human)*7 – 0.00726 0.005 Bourassa et al. (2011)
50% Dissolution time*8 H – 4.3
Dissolution shape*8 – – 0.9
*1Clog MA: calculated (c) logarithmic (log) value of the membrane afﬁnity (MA).
*2ClogMA as a measure for lipophilicity was calculated in silico based on the chemical structure of tamoxifen by a Bayer in-house cheminformatics tool that uses a
fragment-based quantitative structure-activity relationship (QSAR)-method.
*3Log D 37˚C: experimentally determined logarithmic (log) value of tamoxifen distribution (D) between buffer of pH 7.4 and dimyristoylphosphatidylcholine liposomes
at 37˚C.
*4fu (rat): fraction unbound in rat plasma.
*5Clog Kd HSA: calculated (c) logarithmic (log) value of the dissociation constant (Kd) of tamoxifen of human serum albumin (HSA).
*6Ka HSA: association constant (Ka) of tamoxifen to human serum albumin (HSA).
*7fu (human): fraction unbound in human plasma calculated internally in PK-Sim® based on log KD HSA calculated from Ka (Bourassa et al., 2011).
*8Parameters of the Weibull function.
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FIGURE 3 | Results of the rat PBPK-model for intravenous tamoxifen.
(A) Plasma concentration–time proﬁles following application of i.v. single
dose (SD) of 2mg/kg tamoxifen to rat. The gray dashed line represents the
predicted proﬁle, colored lines represent simulated proﬁles after
reﬁnement of lipophilicity. Blue and red symbols show experimental data
taken from the literature. PBPK-models for male (blue) and female rat (red)
differ exclusively in terms of the input parameter clearance. (B) Predicted
versus observed data to show model predictivity. (C) Simulated versus
observed data to show model improvement after reﬁnement of
lipophilicity.
PBPK-model in a female individual
The rat PBPK-model was subsequently scaled to human physi-
ology (i.e., to an average European female breast cancer patient;
Table 2),while the substance-related physico-chemical input para-
meters remained unchanged. The fraction unbound of tamox-
ifen in plasma (fu) differs between rat and human and was,
therefore, also adapted (Yang et al., 2010; Bourassa et al., 2011;
Table 1).
According to the current dose regimen of tamoxifen for breast
cancer patients, simulations were conducted for 20mg tamoxifen
per os (p.o.) and compared to literature data. These data were
either taken from investigations following administration of 20mg
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Table 2 | Species-specific model parameters for the European female individuals.
Parameter Unit Reference value Used in simulation Range used in population simulation Reference
Age Years 60 60 40–80 Demographic data from literature*1
Body weight kg 65.4 65.4 50.4–80.4
Body height cm 163.4 163.4 153.4–173.4
Body mass index kg/m2 24.5 24.5
Gastric emptying time h 0.5 1
Intestinal transit time h 4 24*2
*1Mean demographic data taken from the literature (Fabian et al., 1981; Bratherton et al., 1984; Soininen et al., 1986; De Vos et al., 1992, 1998; Johnston et al., 1993;
Buzdar et al., 1994; Lien et al., 1995; Peyrade et al., 1996; Dowsett et al., 1999, 2001; Guerrieri-Gonzaga et al., 2001; Decensi et al., 2003; Gallicchio et al., 2004;
Kisanga et al., 2004; Hutson et al., 2005; Jin et al., 2005; Borges et al., 2006; Gjerde et al., 2008, 2010).
*2An intestinal transit time of 24 h was integrated into the PBPK-model of oral dosing tamoxifen to female breast cancer patients in order to take into account
absorption of the substance additionally from distal segments of the intestine as indicated by the data and further discussed in the text.
tamoxifen p.o. or data were normalized to a dose of 20mg tamox-
ifen p.o. assuming linear PK in the applied dose range (Etienne
et al., 1989; Fuchs et al., 1996; Stearns et al., 2003; Kisanga et al.,
2004; Jin et al., 2005; Furlanut et al., 2007; Gjerde et al., 2008,
2010; Jaremko et al., 2010; Madlensky et al., 2011; Murdter et al.,
2011).
As tamoxifen is a Biopharmaceutics Classiﬁcation System
(BCS) Class II compound and hence poorly soluble, an empir-
ical dissolution function was integrated into the PBPK-model
(Table 1) in order to account for solubility limitation of oral
absorption (Tukker et al., 1986; Bergstrom et al., 2003; Kasim
et al., 2003; Choi and Kang, 2008; Fagerberg et al., 2010). Fur-
thermore, tamoxifen and its metabolites have been reported to
undergo entero-hepatic circulation and subsequent re-absorption
(Fromson et al., 1973a,b; Lien et al., 1988; Buckley and Goa,
1989; Kisanga et al., 2005). This phenomenon was described
in the model assuming prolonged intestine transit time (ITT;
Table 2). As the model was built with the continuous tube
model of the gastrointestinal tract (GI-tract), which does not
include the large intestine, this prolonged ITT additionally
takes into account the probability that absorption processes
may not only occur in proximal segments of the intestine but
also in distal parts of the GI-tract (Willmann et al., 2003b,
2004).
In a ﬁrst simulation, the elimination of tamoxifen in humans
was predicted from the speciﬁc hepatic clearance (CLspec) of a
female rat in combination with a scaling factor of 0.434 that
was taken from reported differences of initial formation rates
of tamoxifen metabolites between female rat liver microsomes
and female human liver microsomes (Lim et al., 1994; Table 4).
This approach turned out to slightly over-predict the clearance
observed in humans (Figure 4). Therefore, the input parame-
ter for the total hepatic clearance was re-adjusted in a second
step in order to match the experimental data (Table 4; Etienne
et al., 1989; Fuchs et al., 1996; Furlanut et al., 2007). In addition,
a slight decrease of fu (Table 1) improved the agreement between
the simulated and experimentally observed data (Figure 4). This
tamoxifenPBPK-model for an average female breast cancer patient
formed the basis for the coupled model that also includes the three
metabolites.
Development of a CYP2D6 EM-speciﬁc coupled
tamoxifen–tamoxifen metabolites PBPK-model in a female
individual
At ﬁrst, PBPK-models for the three metabolites (NDM-TAM,
4-OH-TAM, and endoxifen) in the average European female indi-
vidual (Table 2) had to be established according to the PBPK-
model for tamoxifen. As – to the best of our knowledge, no
plasma concentration–time data following i.v. dosing of the three
metabolites are available, neither in rats nor in humans, the input
parameters were taken from the literature and integrated into the
respective PBPK-models. Lipophilicity values predicted with the
in-house method were scaled by the same difference of reference
versus simulated as described for tamoxifen. Likewise, fu values
were scaled by the same factor of reference versus simulated as for
tamoxifen (Tables 1 and 3). For endoxifen, plasma concentration–
time data following single oral administration of endoxifen were
recently determined in healthy male volunteers. In addition, the
total body clearance of endoxifen was reported by the authors,
which was taken as reference input parameter to describe endox-
ifen clearance (Table 5; Ahmad et al., 2010). These data were used
to optimize the lipophilicity value of endoxifen in the same way
as described above for tamoxifen (data not shown). It was found
that a lipophilicity value of 3.8 yields the best agreement with the
reported data (Table 3). Hence, the value was used for all further
simulations of endoxifen.
To couple the tamoxifen model with the models for NDM-
TAM, 4-OH-TAM, and endoxifen, ﬁrst the total hepatic clearance
of tamoxifenwas split into several processes. Each process serves as
a source for the metabolites, which are consequently formed in the
intracellular space of the liver. All hepatic clearance processes were
implemented as Michaelis–Menten kinetic processes (Table 4).
Vmax-values derived from Desta et al. (2004) for implemented
biotransformation routes of tamoxifen via CYPs and Vmax-values
derived from Kaku et al. (2004) for glucuronidation of tamox-
ifen were scaled by two speciﬁc factors (10 and 2, respectively;
Table 4) to be consistent with the previously determined total
hepatic CLspec of tamoxifen in human female liver and observed
data. The biotransformation steps thus provide the link between
the two PBPK-models of NDM-TAM and 4-OH-TAM to the par-
ent drug PBPK-model (Tables 4 and 5). In terms of NDM-TAM
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FIGURE 4 | European female individual PBPK-model for oral
tamoxifen versus experimental data. (A) Plasma concentration–time
proﬁles of tamoxifen following administration of a single oral dose of
20mg tamoxifen to an average European female individual. The blue line
represents the predicted proﬁle; the red line shows simulation results
after reﬁnement of the speciﬁc hepatic clearance (CLspec) and f u. Black
symbols indicate experimental data taken from the literature.
(B) Predicted versus observed data to show model predictivity.
(C) Simulated versus observed data to show model improvement after
adjustment of CLspec and f u.
Table 3 | Substance-specific parameters for PBPK-model development of NDM-TAM, 4-OH-TAM, and endoxifen in European female individuals.
Parameter Unit Reference value Used in simulation Reference
N -DESMETHYLTAMOXIFEN-SPECIFIC PARAMETERS
Molecular weight g/mol 357.49 357.49 PubChem
Clog MA log unit 3.57 4.37 In-house method
Clog K d HSA Mol/L −4.55 −4.24 In-house method
f u* – 0.00549 0.00378
4-HYDROXYTAMOXIFEN-SPECIFIC PARAMETERS
Molecular weight g/Mol 387.52 387.52 PubChem
Clog MA log unit 3.37 4.17 In-house method
Log D 37˚C log unit 4.52 Custódio et al. (1991)
Clog K d HSA M −4.59 In-house method
K a HSA M−1 1.8×104 Bourassa et al. (2011)
K d HSA M 5.56×10−5 Bourassa et al. (2011)
Log K d HSA M −4.26 −4.26 Bourassa et al. (2011)
f u – 0.00817 0.00563 Bourassa et al. (2011)
ENDOXIFEN-SPECIFIC PARAMETERS
Molecular weight g/Mol 373.49 373.49 PubChem
Clog MA log unit 3.5 3.8 In-house method
Clog K d HSA M −4.63 In-house method
K a HSA M−1 2×104 Bourassa et al. (2011)
K d HSA M 5×10−5 Bourassa et al. (2011)
Log K d HSA M −4.3 −4.3 Bourassa et al. (2011)
f u – 0.00624 0.0043 Bourassa et al. (2011)
*The value of fu for NDM-TAM was calculated from the predicted value taken from in-house method and the calculated mean difference between predicted and
experimental values from tamoxifen, 4-OH-TAM, and endoxifen since NDM-TAM binding to HSA was not investigated (Bourassa et al., 2011).
and 4-OH-TAM clearance processes, Michaelis–Menten kinetics
from human liver microsome assays were integrated following the
same logic (Nishiyama et al., 2002; Desta et al., 2004), thereby
establishing a link to the endoxifen PBPK-model. All implemented
clearance processes are deemed to best represent a CYP2D6 EM
phenotype (Figure 1, Tables 4 and 5).
In vitro data indicate that about 45% of total 4-OH-
TAM are formed via CYP2D6 out of tamoxifen and that
CYP2C9 catalyzes the formation of 46% of total 4-OH-
TAM, whereas the remaining 9% of total 4-OH-TAM is
formed out of tamoxifen via other CYP iso-enzymes (Coller
et al., 2002). This mass balance of 4-OH-TAM-formation out
of tamoxifen was integrated into the coupled PBPK-model
(Table 4).
The coupled PBPK-model was subsequently used to simu-
late the plasma concentration–time proﬁles of tamoxifen and the
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Table 4 | Parameters describing tamoxifen clearance in rat and European female individuals.
Parameter Unit Reference value Used in simulation Reference Geo SDVmax_spec used in
population simulation*1
RAT-SPECIFIC CLEARANCE PARAMETERS
Total plasma CL*2 mL/min/kg 18.7±4.49 – Shin et al. (2008) –
18.8±3.11 – Piao et al. (2008) –
22.4±1.33 – Yang et al. (2010) –
Mean total plasma CLmale mL/min/kg 19.97 19.97 Mean value*3 –
Hepatic CLspec male 1/min – 92.7 –
Mean total plasma CLfemale mL/min/kg – 13.6 –
Hepatic CLspec female 1/min – 50 –
EUROPEAN FEMALE INDIVIDUALS-SPECIFIC CLEARANCE PARAMETERS
Hepatic CLspec scaled rat 1/min 21.7 Lim et al. (1994) –
Hepatic CLspec adjusted 1/min 19.8 –
Km tam→NDM-tam*4 μM 2.7 2.7 Desta et al. (2004) –
V max tam→NDM-tam*5 pmol/min/mg protein 77.75 *10 Desta et al. (2004) 1.5
Km tam→4-OH-tam*6 μM 0.75 0.75 Desta et al. (2004) –
V max all tam→4-OH-tam pmol/min/mg protein 2.5 *10 Desta et al. (2004) –
V max CYP2D6 tam→4-OH-tam pmol/min/mg protein 1.125 *10 Coller et al. (2002) 1.6
V max CYP2C9 tam→4-OH-tam pmol/min/mg protein 1.15 *10 Coller et al. (2002) 1.45
V max others tam→4-OH-tam pmol/min/mg protein 0.225 *10 Coller et al. (2002) 1.4
Km tam→M-I*7 μM 4.85 4.85 Desta et al. (2004) –
V max tam→M-I pmol/min/mg protein 7.4 *10 Desta et al. (2004) 1.5
Km tam→ α-OH-tam*8 μM 1.5 1.5 Desta et al. (2004) –
V max tam→ α-OH-tam pmol/min/mg protein 6.5 *10 Desta et al. (2004) 1.5
Km tam→3-OH-tam*9 μM 4.9 4.9 Desta et al. (2004) –
V max tam→3-OH-tam pmol/min/mg protein 1.45 *10 Desta et al. (2004) 1.5
Km tam→4′ -OH-tam*10 μM 13.1 13.1 Desta et al. (2004) –
V max tam→4′ -OH-tam pmol/min/mg protein 3.45 *10 Desta et al. (2004) 1.4
Km tam→N -gluc-tam*11 μM 35.8 35.8 Kaku et al. (2004) –
V max tam→N -gluc-tam pmol/min/mg protein 89.3 *2 Kaku et al. (2004) 1.4
*1Geo SD Vmax_spec: geometrical (geo) standard deviation (SD) of the speciﬁc (spec) Vmax used in population simulations (Dorne et al., 2003).
*2CL: clearance.
*3Mean value calculated from (Piao et al., 2008; Shin et al., 2008; Yang et al., 2010).
*4Km: Michaelis–Menten constant; substrate concentration at 50% of maximum velocity of reaction; measurement for substrate afﬁnity; tam: tamoxifen; NDM-tam:
N-desmethyltamoxifen.
*5Vmax: maximum velocity of reaction.
*64-OH-tam: 4-hydroxytamoxifen.
*7M-I: metabolite I.
*8α-OH-tam: alpha-hydroxytamoxifen.
*93-OH-tam: 3-hydroxytamoxifen.
*104′-OH-tam: 4′-hydroxytamoxifen.
*11N-gluc-tam: tamoxifen-N-glucuronide.
metabolites included over a period of 12months with a once daily
administration of 20mg tamoxifen. The simulation results were
compared to observed data (Figure 5; Etienne et al., 1989; Fuchs
et al., 1996; Stearns et al., 2003; Jin et al., 2005; Furlanut et al., 2007;
Gjerde et al., 2008, 2010; Jaremko et al., 2010; Irvin et al., 2011;
Madlensky et al., 2011; Murdter et al., 2011). Data collected later
than 12months were used as if they were collected after 12months
assuming that steady-state kinetics are reached by 1 year (Buzdar
et al., 1994). The simulated tamoxifen plasma concentration was
well in line with the observed data (Figure 5; solid blue line). How-
ever, the proﬁles of the metabolites (Figure 5; dashed lines) were
still over-predicted due to the not yet scaled metabolites’ clearance
processes (Table 5).
Consistent with the PBPK-model development of the parent
drug, clearance data taken from Desta et al. (2004) were subse-
quently scaled by a factor of 10 (Tables 4 and 5). Data taken from
Nishiyama et al. (2002) was adjusted in terms of Vmax by a fac-
tor of 5 (Table 5). No further reﬁnement of endoxifen clearance
proved necessary (Table 5).
The ﬁnal comparison of simulated and experimental data
reveals that the PBPK-model describes the formation and mainte-
nance of tamoxifen andmetabolites steady-state kinetics (Figure 5;
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Table 5 | Parameters describing the clearance of NDM-TAM, 4-OH-TAM, and endoxifen in European female individuals.
Parameter Unit Reference value Simulated
value
Reference Geo SDVmax_spec used in
population simulation
EUROPEAN FEMALE INDIVIDUALS-SPECIFIC CLEARANCE PARAMETERS
N-desmethyltamoxifen-speciﬁc clearance parameters
Km NDM-tam→ α-OH-NDM-tam*1 μM 5.3 5.3 Desta et al. (2004) –
V max tam→ α-OH-NDM-tam pmol/min/mg protein 57 *10 Desta et al. (2004) 1.5
Km NDM-tam→NDDM-tam*2 μM 6.55 6.55 Desta et al. (2004) –
V max NDM-tam→NDDM-tam pmol/min/mg protein 44.4 *10 Desta et al. (2004) 1.5
Km NDM-tam→endoxifen μM 5.2 5.2 Desta et al. (2004) –
V max NDM-tam→endoxifen pmol/min/mg protein 19.1 *10 Desta et al. (2004) 1.6
4-Hyroxytamoxifen-speciﬁc clearance parameters
Km 4-OH-tam→3,4-DOH-tam*3 μMol 4.4 4.4 Desta et al. (2004) –
V max 4-OH-tam→3,4-DOH-tam pmol/min/mg protein 85.5 *10 Desta et al. (2004) 1.5
Km 4-OH-tam→endoxifen μMol 7.9 7.9 Desta et al. (2004) –
V max 4-OH-tam→endoxifen pmol/min/mg protein 102 *10 Desta et al. (2004) 1.5
Km 4-OH-tam→ cis-gluc-4-OH-tam*4 μMol 7.85 7.85 Desta et al. (2004) –
V max 4-OH-tam→ cis-gluc-4-OH-tam*5 pmol/min/mg protein 6284.29 *5 Nishiyama et al. (2002) 1.4
Km 4-OH-tam→ trans-gluc-4-OH-tam μMol 38.95 38.95 Nishiyama et al. (2002) –
V max 4-OH-tam→ trans-gluc-4-OH-tam*5 pmol/min/mg protein 175.41 *5 Nishiyama et al. (2002) 1.4
Km 4-OH-tam→ cis-sulf-4-OH-tam*6 μMol 44.15 44.15 Nishiyama et al. (2002) –
V max 4-OH-tam→ cis-sulf-4-OH-tam*5 pmol/min/mg protein 42.12 *5 Nishiyama et al. (2002) 1.4
Km 4-OH-tam→ trans-sulf-4-OH-tam μMol 17.6 17.6 Nishiyama et al. (2002) –
V max 4-OH-tam→ trans-sulf-4-OH-tam*5 pmol/min/mg protein 765.58 *5 Nishiyama et al. (2002) 1.4
Endoxifen-speciﬁc clearance parameters
total plasma CL L/h/kg 0.085 0.085 Ahmad et al. (2010) –
hepatic CLspec 1/min – 17.197 1.4
*1α-OH-NDM-tam: alpha-hydroxy-N-desmethyltamoxifen.
*2NDDM-tam: N-didesmethyltamoxifen.
*33, 4-DOH-tam: 3, 4-dihydroxytamoxifen.
*4Gluc-4-OH-tam: glucuronides of 4-hydroxytamoxifen.
*5Vmax-values have been calculated by means of the given Km values and the speciﬁc formation rate determined in the human liver microsomes assay measured at a
known substrate concentration using the Michaelis–Menten equation.
*6Sulf-4-OH-tam: sulfates of 4-hydroxytamoxifen.
solid lines) very well. It is noticeable from the observed data
that tamoxifen and its metabolites show a high inter-individual
variability in plasma concentrations (Langan-Fahey et al., 1990;
Peyrade et al., 1996). To address the inter-individual variability,
PBPK-population simulations were set up for both, the CYP2D6
extensive metabolizer and the poor metabolizer.
PBPK-population model for CYP2D6 EM and PM phenotypes
The coupled PBPK-model of tamoxifen,NDM-TAM,4-OH-TAM,
and endoxifen representing an average European female subject of
CYP2D6 EM phenotype was adapted to a CYP2D6 PM phenotype
by integrating known CYP2D6 PM phenotype-speciﬁc enzyme
activities (Coller et al., 2002).
In the CYP2D6 EM phenotype-speciﬁc coupled PBPK-model,
it is assumed that CYP2D6 catalyzes the formation of 4-OH-TAM
out of tamoxifen to an extent of 45% and is exclusively respon-
sible for endoxifen formation out of NDM-TAM (Coller et al.,
2002; Desta et al., 2004; Murdter et al., 2011; Figure 1, Tables 4
and 5). The two CYP2D6 EM phenotype-speciﬁc CYP2D6 Vmax-
values were thus scaled by a factor of 0.015 in order to represent
the negligible enzyme activity of CYP2D6 in female individuals of
PM phenotype (Coller et al., 2002). All other parameters of the
CYP2D6 EM phenotype-speciﬁc PBPK-model parameterization
were kept constant. Simulations of 20mg tamoxifen daily for a
period of 12months were performed as described above.
The implemented mass balance of metabolite formation result-
ing from the enzyme kinetics reported by several groups assumes
that approximately 10% of endoxifen is formed via 4-OH-TAM
(Coller et al., 2002; Nishiyama et al., 2002; Desta et al., 2004;
Kaku et al., 2004). Recently, one group postulated that 20–30% of
total endoxifen is formed via 4-OH-TAM (Murdter et al., 2011).
In order to evaluate this hypothesis, the coupled CYP2D6 EM
phenotype-speciﬁc PBPK-model was modiﬁed to alternatively
reﬂect the formation of 20, 30, and 40%, respectively, of total
endoxifen from 4-OH-TAM. Each model variant was scaled to the
CYP2D6 PM phenotype by the procedure described above (see
also Table 6).
Based on a few simple input parameters (ethnicity, gender, age,
weight, and height; Table 2), generic populations of individuals
were created taking into account inter-individual variability in
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FIGURE 5 |Tamoxifen and metabolites steady-state kinetics in an
average European female individual of CYP2D6 EM phenotype. Resulting
plasma concentration–time proﬁles of tamoxifen (blue),
N -desmethyltamoxifen (NDM-TAM; black), 4-hydroxytamoxifen (4-OH-TAM;
green), and endoxifen (red) following once daily administration of 20mg
tamoxifen p.o. to an average European female individual of CYP2D6 extensive
metabolizer phenotype over a period of 12months. Dashed lines represent
predicted proﬁles of metabolites, solid lines show simulated proﬁles after
adjustment of V max-values. Dots represent individual data, stars represent
mean data, and plus’ represent median data taken from the literature.
Table 6 | Modification of the coupled CYP2D6 EM phenotype-specific PBPK-model parameterization to alternatively reflect the formation of
20–40% of total endoxifen formation out of 4-OH-TAM and subsequent scale factors for the CYP2D6 PM phenotype-specific PBPK-model
parameterization.
Parameter Unit EM value PM value Reference
∼10% ENDOXIFEN OUT OF 4-HYDROXYTAMOXIFEN
PM factor V max CYP2D6 – – 0.015* Coller et al. (2002)
20% ENDOXIFEN OUT OF 4-HYDROXYTAMOXIFEN
V max 4-OH-tam→endoxifen pmol/min/mgprotein 2.385* 2.385*
V max NDM-tam→endoxifen pmol/min/mgprotein 0.85* 0.01275*
V max 4-OH-tam→Gluc/Sulf pmol/min/mgprotein 3.5* 3.5*
30% ENDOXIFEN OUT OF 4-HYDROXYTAMOXIFEN
V max 4-OH-tam→endoxifen pmol/min/mgprotein 3.57* 3.57
V max NDM-tam→endoxifen pmol/min/mgprotein 0.73* 0.01095*
V max 4-OH-tam→Gluc/Sulf pmol/min/mgprotein 2.25* 2.25*
40% ENDOXIFEN OUT OF 4-HYDROXYTAMOXIFEN
V max 4-OH-tam→endoxifen pmol/min/mgprotein 4.76* 4.76*
V max NDM-tam→endoxifen pmol/min/mgprotein 0.62* 0.0093*
V max 4-OH-tam→Gluc/Sulf pmol/min/mgprotein 0.9* 0.9*
*Gluc, glucuronides; Sulf, sulfates.
physiological parameters such as organ volumes and blood ﬂow
rates (Willmann et al., 2007). In addition, variability can be super-
imposed on non-generic parameters. Tables 1, 4, and 5 present
the chosen settings for generic and non-generic parameters that
were applied to create 1000 female individuals. These can be used
to re-parameterize each of the different coupled PBPK-models of
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tamoxifen,NDM-TAM,4-OH-TAM, and endoxifen for an average
European female subject of CYP2D6 EM phenotype accounting
for∼10–40%of endoxifen formation out of 4-OH-TAM,aswell as
the PMvariants thereof (Table 6).Daily dosing of 20mg tamoxifen
for a period of 12months was simulated in each individual.
Population simulation results of the four CYP2D6 EM Euro-
pean female individual populations and the four scaled CYP2D6
PM European female individual populations were compared to
reported data from female patients of known CYP2D6 phenotype
(Figure 6; Gjerde et al., 2008, 2010; Irvin et al., 2011; Madlensky
et al., 2011; Murdter et al., 2011).
Simulation results of the four CYP2D6 EM individual popula-
tions show that the model parameterizations are able to account
for the high inter-individual variability in PK of tamoxifen and
match all reported median plasma concentration data of NDM-
TAM, 4-OH-TAM, and endoxifen. There is no obvious difference
in simulation results between the four assumed mass balances of
endoxifen formation out of 4-OH-TAM (Figure 6; not all data
shown).
Predictions following the four population simulations of
tamoxifen and metabolites PK in 1000 European female subjects
of CYP2D6 PM phenotype sufﬁciently describe the corresponding
plasma concentration data of tamoxifen, NDM-TAM, and 4-OH-
TAM in all four assumed mass balances (Figure 6; left column,
not all data shown). Endoxifen plasma concentration data is best
reﬂected in the scaled PBPK-model of CYP2D6 PM phenotype
from the CYP2D6 EM phenotype-speciﬁc PBPK-model assuming
30% endoxifen formation out of 4-OH-TAM (Figure 6; right col-
umn) thereby supporting the hypothesis postulated by Murdter
et al. (2011).
DISCUSSION
Tamoxifenwas approved by theU.S. food and drug administration
(FDA) for the treatment of metastatic breast cancer in 1977 and
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FIGURE 6 | Steady-state plasma concentrations of tamoxifen,
NDM-TAM, 4-OH-TAM, and endoxifen in populations of CYP2D6 EM
and PM phenotype. Steady-state plasma concentrations for European
female subject populations (N =1000) of CYP2D6 extensive metabolizer
phenotype (left) and CYP2D6 poor metabolizer phenotype (right).
Box–Whisker-plots indicate the percentiles 5, 25, 50, 75, and 95 of the
population simulations considering ∼10–40% of total endoxifen being
formed out of 4-hydroxytamoxifen (x -axis). Symbols represent
experimental data used for model validation (from left to right: Gjerde
et al., 2010, median + 25th/75th percentile (x-symbol + dots); Gjerde et al.,
2008, median+ range (*-symbol + dots); Madlensky et al., 2011, median
(+-symbol); Murdter et al., 2011, median+ range (*-symbol + dots); Irvin
et al., 2011; median (+-symbol)). Abbreviations in y -axis-label: TAM,
tamoxifen; NDM, N -desmethyltamoxifen; 4OH, 4-hydroxytamoxifen; END,
endoxifen. Abbreviations in x -axis-label: sim, simulated results; exp,
experimental data taken from literature.
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its indication has been expanded gradually during the following
years (Desta et al., 2004). Although millions of women worldwide
have been treatedwith the drug, there is still a lot to be learnt about
tamoxifen.
First, tamoxifen has neither been investigated in terms of
optimal biological dose-ﬁnding nor has its PK been determined
following an i.v. administration to humans, leaving basic PK para-
meters such as volume of distribution, total plasma clearance,
and absolute bioavailability after oral administration undeter-
mined (Decensi et al., 2003). Second, biotransformation routes of
tamoxifen are complex and lead to the formation of a number of
active metabolites that signiﬁcantly contribute to its anti-tumoral
activity (Murdter et al., 2011).
Several polymorphic enzymes are involved in tamoxifen
biotransformation, most importantly CYP2D6 that determines
endoxifen exposure in tamoxifen-treated women. Nevertheless,
after stratifying for CYP2D6 polymorphisms, endoxifen steady-
state plasma concentration remains variable. Murdter et al.
demonstrated that CYP2D6 genotype explains about 38% of
endoxifen variability,which is well in line with results published by
another group (Madlensky et al., 2011; Murdter et al., 2011). This
leads to the assumption that there could be further inﬂuencing
factors such as CYP2C9/2C19 or UGT polymorphisms that may
also have a signiﬁcant impact on tamoxifen PK and biotransfor-
mation to endoxifen (Blevins-Primeau et al., 2009; Ruiter et al.,
2010; Murdter et al., 2011; Van Schaik et al., 2011).
Besides the long use of tamoxifen, the consequences of the high
inter-individual variability in the metabolite pattern on treatment
outcome, in particular in CYP2D6 PM and IM individuals, is still
a subject of vivid discussions.
The presented coupled PBPK-model of tamoxifen and its
most important metabolites provides a useful starting point to
investigate the inﬂuence of certain covariates on tamoxifen PK
and biotransformation to endoxifen such as CYP2D6 phenotype,
ethnicity, or co-administration of other drugs.
In general, it is preferred to build at ﬁrst a PBPK-model for i.v.
administration in order to simulate the drug’s distribution kinetic
in the absence of absorption. This was not possible for tamox-
ifen, because i.v. PK data of this drug has – to the best of our
knowledge – never been measured in humans. Therefore, a rat
i.v. model has been developed based on preclinical PK data (Shin
et al., 2006, 2008; Choi and Kang, 2008; Piao et al., 2008; Shin and
Choi, 2009; Kim et al., 2010; Yang et al., 2010; Li et al., 2011). After
determinationof an appropriate lipophilicity input parameter, this
model was scaled to human individuals by exchanging the species-
speciﬁc physiological parameters while the species-independent
physico-chemical parameters of tamoxifen remained unchanged.
Based on this i.v. scaling approach, the volume of distribution of
tamoxifen in an average adult female individual weighing 65 kg
was calculated to be 34 L/kg which is largely in accordance with
the apparent terminal distribution volume estimated by Lien et al.
(1989; 52–61 L/kg) that was obtained after repeated oral tamoxifen
dosing.
In the next modeling step, the route of drug delivery was
changed to p.o. administration. After adjustment of model para-
meters that affect the dissolution rate, the absorption kinetics
could be very well described. The necessity for these adjustments
arose from the fact that tamoxifen is a poorly soluble (BCS Class
II) drug and thus, dissolution is very likely to determine the rate
of absorption. Moreover, this adjustment has only a minor inﬂu-
ence on the peak-trough ratios after repeated dosing, and does not
drastically affect the average steady-state tamoxifen levels, because
the bioavailability was not affected by the changes. Based on the
presented model, oral absorption of tamoxifen is almost complete
(97%). Together with a small ﬁrst pass effect in the liver (3%), the
simulated oral bioavailability of tamoxifen amounts to 94% (data
not shown).
Overall, the resulting PBPK-model of tamoxifen SD in an aver-
age European female patient was able to describe the observed
plasma concentration–time proﬁles (Figure 4). The slight adapta-
tion of CLspec (Table 4) is supported by the fact that the resulting
total plasma clearance calculated with the model confers to a
reported total plasma clearance reported in the literature as the
model assumes a fraction absorbed of 0.97 (Fuchs et al., 1996). So
far, the model has only demonstrated its applicability in European
breast cancer patients and is – strictly speaking – limited to this eth-
nicity. A translation to other ethnicities, however, should be easily
achievable on the basis of prior knowledge about anthropometric,
physiological, and biochemical differences that are included in the
databases of PK-Sim®.
Unfortunately, there were only few published plasma
concentration–time proﬁles of SD tamoxifen in female breast can-
cer patients available. Data is most often presented in the form
of steady-state plasma concentration in patients receiving tamox-
ifen. Consequently, the dosing schedule in the PBPK-model was
adapted to a repeated daily dosing of 20mg tamoxifen in an aver-
age European female patient. Using prior in vitro information
about tamoxifen’s biokinetics in the form of Michaelis–Menten
constants, the total clearance was split into individual processes
that formed the sources of metabolites. It proved to be necessary
to scale reportedVmax-values of integratedCYPandUGTmetabo-
lism of tamoxifen by scaling factors, respectively, in order to reach
the dimension of the previously determined hepatic CLspec and
match observed plasma concentration–time proﬁles (Tables 4 and
5; Figures 4 and 5). Besides the fact that the scaled Vmax-values
led to a hepatic CLspec that corresponds to the determined hepatic
CLspec of the parent drug, adjusting of absolute Vmax-levels may
be justiﬁed in terms of varying enzyme expression and activity.
Human liver microsome assays performed to investigate the for-
mation of tamoxifen’s primary metabolites by Desta et al. (2004)
already exerted a difference in CYP3A enzyme activity by a factor
of approximately 10. Urinary excretion of tamoxifen was reported
to be very low and hence was not included into the PBPK-model
(Soininen et al., 1986).
After implementation of the individual clearance processes,
the parent drug PBPK-model was extended by PBPK-models for
its two most important primary metabolites and the sequential
PBPK-model of endoxifen,whichwas performed via linkage of the
PBPK-models through speciﬁc enzyme activities of hepatic intra-
cellular metabolism (Figure 2; Coller et al., 2002; Nishiyama et al.,
2002;Desta et al., 2004;Kaku et al., 2004). Simulation of 12months
daily dosing tamoxifen with the coupled PBPK-model showed a
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good match of resulting metabolites plasma concentrations with
experimental data after scaling Vmax-values in a similar approach
as in the tamoxifen PBPK-model (Tables 4 and 5; Figure 5).
Thus, we have established a coupled PBPK-model that is able
to reﬂect the mass balance based on reported enzyme kinetics and
that links formation of endoxifen to preceding 4-hydroxylation
or N -demethylation of tamoxifen (Desta et al., 2004). Accord-
ing to this model, the formation of 45% of total 4-OH-TAM out
of tamoxifen proceeds via the polymorphic CYP2D6. In case of
endoxifen formation from NDM-TAM, CYP2D6 is exclusively
responsible for biotransformation. Performed simulations of
tamoxifen, NDM-TAM, 4-OH-TAM, and endoxifen steady-state
plasma concentration development during a period of 12months
of daily dosing 20mg tamoxifen led to a good description of
tamoxifen, NDM-TAM, and 4-OH-TAM in each the two phe-
notype populations. Endoxifen steady-state plasma concentration
was slightly underestimated only in the CYP2D6 PM phenotype
population (Figure 6).
The quantitative contribution of the two primary tamoxifen
metabolites to the formation of endoxifen has not been inves-
tigated in vivo so far. The mass balance integrated into the
EM phenotype-speciﬁc PBPK-model of tamoxifen metabolism
accounts for ∼10% of total endoxifen formation out of 4-OH-
TAM and is based on several published data (Coller et al., 2002;
Nishiyama et al., 2002; Desta et al., 2004; Kaku et al., 2004).
However, Murdter et al. (2011) postulated in their very recently
published investigation of tamoxifen metabolism in breast can-
cer patients that approximately 20–30% of total endoxifen may be
formed out of 4-OH-TAM.
Hence, the baseline PBPK-model of tamoxifen metabolism in
a CYP2D6 EM phenotype was adjusted to reﬂect 20, 30, and 40%
of total endoxifen formation out of 4-OH-TAM. All four EM
phenotype-speciﬁc PBPK-model parameterizations were subse-
quently scaled to PM phenotype by the factor derived from Coller
et al. (2002) and compared to observed data. The resulting model
parameterizations revealed that an assumption of 30% of total
endoxifen formed out of 4-OH-TAM provides best prediction of
endoxifen steady-state plasma concentration in the CYP2D6 PM
phenotype, thus supporting the hypothesis (Murdter et al., 2011).
Further conﬁrmation in vitro and in vivo may be promising.
The role of CYP2C9 in 4-hydroxylation of tamoxifen – a mat-
ter of fact that has been already assessed in experimental settings
in vitro – is further supported in vivo by Murdter et al. and
could in addition be well described by the established CYP2D6
phenotype-speciﬁc PBPK-models leading to a less pronounced
decrease of 4-OH-TAM in CYP2D6 PMs compared to endoxifen
as also reported in the literature (Coller et al., 2002; Stearns et al.,
2003; Murdter et al., 2011).
The results of population simulations that consider physiolog-
ical variability in European female patient populations represent-
ing each of the two phenotypes are able to account to a large
extend for the reported high inter-individual variability in plasma
concentrations of tamoxifen and its metabolites.
CONCLUSION
A PBPK-model of tamoxifen and its pharmacologically important
metabolites NDM-TAM, 4-OH-TAM, and endoxifen was devel-
oped. This model is able to simulate the PK after single and
repeated oral tamoxifen doses in female breast cancer patients
in dependence of the CYP2D6 phenotype. The analysis regarding
the mass balance thereby supports a recent hypothesis stating a
more prominent role for endoxifen formation from 4-OH-TAM.
The established models can explain PK variability within a popu-
lation and provide a basis for further investigations concerning
tamoxifen PK under varying scenarios such as in populations
of differing geographical origin that exert characteristic distribu-
tions of CYP2D6 phenotypes (Sistonen et al., 2007). Furthermore,
the impact of concomitant treatment with compounds inhibiting
CYP2D6 can in the future be elucidated with this model. Ulti-
mately, by bridging the gap between CYP2D6 phenotype, PK, and
resulting impact on tumor cell growth, a future PBPK/PD-model
of tamoxifen and itsmetabolitesmay provide a useful tool to inves-
tigate the role of CYP2D6 phenotype on the outcome of breast
cancer therapy using tamoxifen.
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